Cardiac Monitors in Washington

HealthCare International Inc. (HCI Fitness) is a Langley, Washington-based medical equipment and rehabilitation device manufacturer serving clinical and home markets since 1992. The company specializes in therapeutic exercise equipment for cardiac rehabilitation, physical therapy, sports medicine, and clinical fitness applications. Primary product lines include recumbent cross-trainers (PhysioStep LXT-700, MDX), recumbent steppers (PhysioStep Pro), treadmills (PhysioMill), total-body trainers (PhysioMax), and upper-body ergometers. The company also distributes complementary brands including MOTOMED (motorized training systems), Cyclus2 (high-performance indoor cycle ergometers), Manuthera (electronic treatment tables), Mediana (body composition analyzers), Cybo systems, and DPE Medical rehabilitation equipment. Products are designed for use in outpatient physical therapy clinics, cardiac rehabilitation programs, assisted living facilities, and residential settings. HCI Fitness offers white-glove delivery, room-of-choice placement, on-site assembly, and nationwide service coverage. The company provides manufacturer's warranty on products and financing options (0% APR through Affirm). Customer base exceeds 300,000 users. Regulatory and certification information not explicitly stated on website.

Cardiac Insight, Inc. is a privately held medical device company based in Bellevue, WA, specializing in cardiac diagnostic products for electrocardiogram (ECG) analysis and arrhythmia detection. The company manufactures two primary product lines: Cardea 20/20, a handheld 12-lead ECG device designed for automated cardiac screening in young athletes and active populations with a reported false-positive rate of approximately 2%, and Cardea SOLO, a 7-day wearable ambulatory ECG sensor with software-assisted analysis. Cardea SOLO delivers interpretive findings in under five minutes with in-office analytics and full data ownership by the prescribing physician. The company's technology uses advanced algorithms adhering to ANSI/AAMI standards for precision ECG interpretation. Founded in 2013, Cardiac Insight leverages expertise from pioneers Dr. Dave Hadley and Dr. Vic Froelicher, who developed the Stanford Criteria for ECG analysis. In 2021, the company partnered with DreamTech, a global electronic components leader. Products feature software-generated reports, fast turnaround times, and clinician-friendly tools including trace views, R.R. intervals, beat morphologies, and measurement calipers. Target markets include sports medicine, primary care, cardiology practices, and research institutions. The company emphasizes streamlined reimbursement processes, cost-effectiveness, and provider support.

Spacelabs Healthcare manufactures patient monitoring systems, diagnostic cardiology equipment, and clinical informatics solutions for acute care, ICU, emergency department, neonatal, and perioperative settings. Core product lines include bedside monitors (Xprezzon, Qube, C50), telemetry systems (AriaTele), central surveillance (Xhibit XC48, XC4), resting ECG systems (CardioExpress series 4012, 5012, SL18A, SL12A, SL6A), Holter monitors and event recorders (Eclipse Pro, Eclipse Mini, Pathfinder SL), and ambulatory blood pressure monitoring (OnTrak, 90217A). The company also offers clinical software tools including SafeNSound Care Coordination (SaaS), Clinical Access, Custom Trends, Print Manager, Smart Disclosure, and Vital Signs Viewer, along with networking and integration solutions (XprezzNet, Flexport interfaces) for EMR connectivity. Spacelabs emphasizes situation awareness design, clinical informatics, and care team performance optimization through its Runway architecture and TeamUp strategies. The company traces its heritage to NASA space program cardiac monitoring development and serves hospitals and healthcare systems across multiple care settings. Technical support includes product manuals, cleaning instructions, service contracts, and cybersecurity advisories.

Inmedix, Inc. is a Washington-based medical diagnostics company specializing in autonomic nervous system (ANS) assessment through heart rate variability (HRV) analysis. The company manufactures the CloudHRV System, an FDA-cleared clinical diagnostic device that provides medical-grade, 5-minute HRV testing to evaluate both sympathetic (fight-or-flight) and parasympathetic (rest/restorative) neuroregulatory function. The CloudHRV System received FDA clearance in 2025 and is currently deployed across multiple states (Washington, Oregon, Michigan, Florida) with coverage by most major insurance plans. The platform is designed to support precision diagnostics by quantifying autonomic nervous system function, with applications in cardiology and general internal medicine. Inmedix emphasizes the clinical and diagnostic value of HRV measurement and has completed over 1,000 procedures since July 2024. The company's scientific approach focuses on immuno-autonomics and the pathophysiological significance of ANS dysfunction in disease assessment and patient stratification.

Kestra Medical Technologies manufactures the ASSURE® Wearable Cardioverter Defibrillator (WCD) system, a non-invasive, wearable medical device designed to protect patients at elevated risk of sudden cardiac arrest (SCA). The system targets heart failure patients and those with reduced left ventricular ejection fraction (LVEF ≤35%) awaiting clinical improvement or subsequent therapeutic intervention. The ASSURE system comprises three integrated components: the wearable defibrillator device with autonomous arrhythmia detection and highly effective defibrillation therapy; the Kestra CareStation™, a cloud-based remote patient data management platform enabling clinician oversight and patient data integration; and the ASSURE patient mobile application to enhance compliance and patient engagement during recovery. The company positions itself at the intersection of digital health, smart wearables, mobile connectivity, and cardiac protection. Kestra's clinical evidence includes the ACE-PAS (ASSURE® WCD Clinical Evaluation Post-Approval Study), described as the largest prospective real-world study of wearable defibrillators to date, demonstrating safety, performance, and real-world effectiveness. The device is FDA-cleared and represents a modern approach to temporary cardiac risk management in ambulatory and home settings. Kestra serves cardiologists, hospitals, and heart failure programs across the United States and maintains international presence.

Fukuda Denshi USA, Inc. is the North American subsidiary of Fukuda Denshi, a global manufacturer of integrated patient monitoring, diagnostic cardiology, and digital health solutions for acute care, general care, and ambulatory settings. The company specializes in bedside and central station patient monitoring systems, including multiparameter monitors (vital signs, ECG, blood pressure, oxygen saturation), portable monitoring devices, and diagnostic cardiology/vascular testing equipment (ECG, stress testing systems, echocardiography systems). Fukuda's product portfolio includes the DS-1800 Central Station and LXN-1000 series portable monitors designed for flexible deployment across clinical workflows. The company also offers interoperability and digital health solutions that integrate with existing hospital information systems and EHRs, emphasizing configurable, seamless integration without requiring workflow changes. Fukuda maintains a support infrastructure including technical support, training, and field service capabilities. Products are designed for hospital acute care units, ICUs, general care floors, and outpatient diagnostic labs. The company emphasizes ease of use, installation simplicity, and cost-effectiveness. Service capabilities include training programs and technical support accessible via phone and online support center.